MannKind Corporation

📍 Danbury, United States👥 541 employees💰 Last funded Dec 2020
Pharmaceutical Manufacturing🌐 mannkindcorp.com
Website LinkedIn
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Please visit mannkindcorp.com to learn more
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in MannKind Corporation?
MannKind Corporation has 2 investors on record on gritt.io.
When did MannKind Corporation last raise funding?
The most recent investment in MannKind Corporation recorded on gritt.io was in December 2020.
What industry is MannKind Corporation in?
MannKind Corporation operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is MannKind Corporation based?
MannKind Corporation is headquartered in Danbury, United States.